| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $95.57B | +8.1% |
| Cost of Revenue | $74.32B | +10.0% |
| Gross Profit | $21.25B | +1.8% |
| R&D Expense | $3.06B | +9.3% |
| SG&A Expense | $11.95B | -7.0% |
| Operating Income | $6.24B | +19.7% |
| Pre-tax Income | $5.05B | +29.9% |
| Income Tax | $472.0M | -31.8% |
| Net Income | $4.59B |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.63B | -50.7% |
| Accounts Receivable | $10.30B | +10.2% |
| Inventory | $6.72B | +85.4% |
| Current Assets | $36.23B | +0.8% |
| Total Assets | $79.75B | -2.9% |
| Current Liabilities | $46.53B | -4.1% |
| Long-term Debt | $24.57B | -5.5% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $4.52B | -47.9% |
| Capital Expenditures | $2.65B | -3.8% |
| Investing Cash Flow | -$2.21B | +20.4% |
| Financing Cash Flow | -$5.82B | +18.0% |
| Free Cash Flow | $1.87B | -68.4% |
| +43.0% |
| EPS (Basic) | $6.51 | +38.2% |
| EPS (Diluted) | $6.38 | +38.7% |
| Total Liabilities |
| $81.13B |
| -3.9% |
| Stockholders' Equity | -$1.48B | +38.4% |